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Pseudomyxoma peritonei (PMP) is best treated by surgery. It was formerly treated by 
serial debulking. The current gold standard is complete cytoreductive surgery (CRS) to 
be followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Improved survival 
figures for patients treated by CRS and HIPEC combined have been reported recently. 
The aim of this PhD research was to evaluate (I) the outcome of patients treated by 
serial debulking in Helsinki University Central Hospital, (II) investigate the clinical 
manifestation of the disease, (III) assess the feasibility of CRS and HIPEC modality in 
combination, and (IV) compare results of serial debulking and CRS with HIPEC in 
patients with PMP. 
The surgical data and the survival outcome of 33 patients that were treated by serial 
debulking were analyzed in study I. The symptoms and signs of 82 patients with PMP 
were investigated in study II. Study III included 90 patients, who were evaluated in our 
facility and then given HIPEC when practicable. The characteristics that were 
associated with technically successful administration of HIPEC were analysed. The 
outcome of 87 patients treated in the HIPEC era was compared with those treated before 
the HIPEC era in study IV. 
The 5-year and 10-year overall survival (OS) rates were 67% and 31%. Four patients 
(12%) presented with no apparent evidence of disease at the completion of follow-up 
(I). The most common symptom of PMP was abdominal pain in 23% of the cases (II). 
Of 53 women, 26 (49%) underwent their initial operations because of presumed ovarian 
tumour. Of 29 men, 13 (45%) underwent their initial operations with a suspicion of 
PMP. Of the 90 patients assessed, 56 (62%) were feasible for HIPEC (III). Low-grade 
tumour (P=0.013), age under 65 (P=0.004), and serum CEA under 5.0μg/L (P=0.003) 
were associated with successful administration of HIPEC. The 5-year OS rates were 
69% for the HIPEC era and 67% for the debulking era (IV). The proportion of patients 
who presented with no evidence of disease was higher for the HIPEC-era group than for 
the debulking-era group (54% vs. 24%). 
Patients who were treated by CRS and HIPEC combined managed well, but it is 
unfeasible to deliver HIPEC to every patient. A comparison of the 5-year OS rates of 
HIPEC era with those of the debulking era showed them to be approximately equal, 
when the whole patient population was included for the comparison. The natural 
progression of PMP is slow and thus the survival difference may only become apparent 
in follow-up periods in excess of 5-years. The proportion of patients who had 
undergone curative treatment may be higher in the HIPEC era.
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5-FU = 5-fluorouracil 
C = Celsius 
CC = completeness of cytoreduction 
CA 12-5 = carbohydrate antigen 12-5  
CA 19-9 = carbohydrate antigen 19-9  
CEA = carcinoembryonic antigen 
CK = cytokeratin 
CRS = cytoreductive surgery 
CT = computed tomography 
CTCAE = Common Terminology Criteria for Adverse Events 
DFS = disease-free survival 
DSS = disease-specific survival 
EPIC = early postoperative intraperitoneal chemotherapy 
DPAM = disseminated peritoneal adenomucinosis 
HAM = human alveolar macrophage 
HIPEC = hyperthermic intraperitoneal chemotherapy 
HUCH = Helsinki University Central Hospital 
LAMN = low-grade appendiceal mucinous neoplasm 
LOH = loss of heterozygosity 
MANEC = mixed adenoneuroendocrine carcinoma of appendix 
MCP-L = low grade mucinous carcinoma peritonei 
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MCP-H = high grade mucinous carcinoma peritonei 
mL = milliliter 
M-LMP = mucinous neoplasm of low malignant potential 
MMC = mitomycin C 
MRI = magnetic resonance imaging 
M-UMP = mucinous neoplasm of uncertain malignant potential 
OS = overall survival 
PALGA = Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief 
PC = peritoneal carcinomatosis 
PCI = peritoneal cancer index 
PET = positive emission tomography 
PFS = progression-free survival 
PMCA = peritoneal mucinous carcinomatosis 
PMCA-I/D = peritoneal mucinous carcinomatosis with intermediate or discordant 
features 
PMP = pseudomyxoma peritonei 
SC = systemic chemotherapy 
WHO = World Health Organization 
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The challenging disease of Pseudomyxoma peritonei (PMP) is best treated by surgery 
and was formerly treated by serial debulking [1]. The current gold standard is complete 
cytoreductive surgery (CRS) to be followed by hyperthermic intraperitoneal 
chemotherapy (HIPEC) [2]. Improved survival figures for patients treated by CRS and 
HIPEC combined have been reported in a recent meta-analysis [3]. However, it is worth 
considering the historical background to this disease in order to understand the 
difficulties and complexities of diagnosing and treating it. 
???? ?????????????????????
The term “pseudomyxoma” comprises the prefix pseudo-, (from the Greek “false, 
lying”), -myx- (muxa from the Greek “mucus”), and suffix –oma (from the Greek 
“process” or “action”. Oma also means tumour in contemporary medical nomenclature. 
Thus, pseudomyxoma peritonei is a mucoid tumour of the peritoneum that resembles 
but is not, myxoma. Myxoma is instead a rare tumour of the primitive connective tissue 
and is located most commonly in the heart.  
The first descriptions of PMP are dated in the 19th century. One of the first persons 
attributed to having described a benign mucocele of the appendix was the Bohemian 
nobleman and pathologist Karl von Rokitansky in 1842. His original article could not be 
traced, but Weaver described Rokitansky´s contribution to oncology in 1937 [4]. A 
gynaecologist named Werth introduced the term pseudomyxoma peritonei and reported 
the syndrome to be related to an ovarian neoplasm in 1884 [5]. In 1901, Frankel 
reported the association between pseudomyxoma and appendiceal cysts [6]. 
Woodruff? ???? ???????? proposed in 19?? that the aetiology of PMP is malignant 
appendiceal mucocele and reported that its peritoneal spread was metastatic [7]. During 
the 20th century there was debate about whether the origin of PMP was the appendix or 
the ovary [8, 9]. The current opinion is, that the appendix can be identified as the origin 
in the majority of cases [10, 11]. 
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PMP is a clinical term.  It is characterized by the accumulation of mucinous ascites 
within the peritoneal cavity. An epithelial neoplasm arises within the appendiceal lumen 
and consequently the lumen per se becomes occluded. This occlusion finally causes a 
rupture in the wall of the appendix and therefore mucus containing epithelial cells is 
spilled within the abdominal cavity [12]. In the majority of cases, this process is 
subclinical [13]. The natural progression of the disease is usually moderately slow, 
although rapid advancement is also seen on occasions. The speed of progression is 
related to the histology of the tumour. The typical course of disease comprises tumour 
spread on the peritoneal surfaces, but invasion of the organs is also seen, especially in 
cases with a high-grade histology. Haematogeneous metastases are rarely seen. 
Nevertheless, those that can be seen are found in the livers or lungs of patients with 
high-grade histology. Eventually the progressive amount of mucus causes dyspnea, 
gastrointestinal obstruction, malnutrition, hydronephrosis, and other organ 
malfunctioning. The condition is lethal without surgical intervention.  
?????????????????
PMP is an uncommon syndrome.  A population based study conducted by Smeenk et al. 
used the nationwide database of the Netherlands and reported an annual incidence of 
PMP approaching 2 per million [14]. Another Dutch study, in which data were retrieved 
from the Eindhoven Cancer Registry noted an increase in age-standardized incidence of 
appendiceal mucinous adenocarcinoma that varied between 0.6 to 1.9 per million in 
women and from 0.4 to 1.0 per million in men [15]. The study period was 1980 to 2010 
and the data cover a large part of the southern Netherlands, which comprises about 2.3 
million inhabitants. The increasing trend in the incidence was explained by the 
increasing awareness of PMP and better registration of the specific diagnosis. Notably, 
only malignant tumours were included in their study. Thus, the incidence they reported 
would be assumed to give an underestimation, if the whole spectrum of PMP regardless 
the histological grade were to have been analyzed. 
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The study by Smeenk et al. noted that a total of 167 744 appendectomies were 
performed in the Netherlands in the 10-year period of 1995 to 2005 [14]. A search was 
undertaken in the nationwide pathology database of the Netherlands (PALGA) and an 
appendiceal lesion was identified in 1482 of those specimens (0.9%). Thus, the annual 
incidence of appendiceal lesion is 9 per million. Of 1482 patients with an appendiceal 
lesion, 138 (9%) developed PMP. The chance of developing PMP was related to the 
type of lesion. Patients with a mucinous epithelial neoplasm developed PMP in 114 
cases (20%), patients with non-mucinous epithelial neoplasm developed PMP in 13 
cases (3%), and patients with mucocele in 11 cases (2%). 
To the best of my knowledge, no data of epidemiology of PMP in Finland has hitherto 
been published. 
???????????????????
 The classification of PMP is indeed challenging. Various classification schemes have 
been proposed and have been used to grade PMP [16-20]. The following section will 
examine more closely the schemes considered to be the most relevant for the debate on 
classification. The studies presented were chosen to represent different aspects of the 
debate. 
Ronnett’s criteria for three distinct PMP groups were introduced in 1995 [18]. These 
criteria have since been widely used in the literature on PMP. According to the criteria, 
PMP can be divided into disseminated peritoneal adenomucinosis (DPAM), peritoneal 
mucinous carcinomatosis (PMCA), and peritoneal mucinous carcinomatosis with 
intermediate or discordant features (PMCA-I/D) by histopathological features. The 
peritoneal lesions in the DPAM group consist of scant, histologically low-grade 
mucinous epithelium within abundant mucin. The epithelium displays minimal mitotic 
activity and cytological atypia. The peritoneal lesions of the PMCA group consist of 
mucinous epithelium forming glands and/or signet ring cells. The amount of epithelium 
is more abundant than for the DPAM group. Cytological atypia and architectural 
complexity are sufficient to establish a diagnosis of mucinous carcinoma. Invasion of 
other organs/lymph nodes often manifest. The PMCA-I group consists of lesions 
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demonstrated predominantly as features of DPAM. However, focal areas of well-
differentiated mucinous carcinoma are present. The PMCA-D group consists of 
peritoneal lesions with mucinous adenocarcinoma, often with signet ring cell 
differentiation and without low-grade epithelium. Despite the peritoneal lesions, the 
primary lesion in the appendix lacks evidence of invasive features. 
Bradley et al. published a series of 101 patients with mucinous ascites related to primary 
appendiceal lesions in 2006 [21]. First, those authors classified the patient population 
into three groups: DPAM, PMCA, or PMCA-I according to Ronnett’s criteria. There 
was the one exception of the signet-cell component. Those cases with the presence of 
signet cell were classified as PMCA and not as PMCA-I. Second, Bradley et al. unified 
DPAM and PMCA-I as one group and PMCA as the other. The amalgamated DPAM 
and PMCA-I group was re-graded to low grade mucinous carcinoma peritonei (MCP-
L). The PMCA group with an addition of cases with signet-cell component was re-
graded to high-grade mucinous carcinoma peritonei (MCP-H).  The rationale for the 
amalgamation of the DPAM and PMCA-I categories was that there was no difference in 
the five-year overall survival (OS) between the groups (61.8 ± 9.2% vs. 68.2 ± 12.1%, 
P= 0.27). On the other hand, the difference in five-year overall survival between PMCA 
and DPAM/PMCA-I combined was evidently significant (37.7% ± 11.2 vs. 62.5% ± 
7.8, P = 0.004). 
Pai and Longacre proposed their differential diagnosis spectrum of appendiceal 
mucinous neoplasms in 2005 [16]. They presented four distinct groups: mucinous 
adenoma, mucinous neoplasm of uncertain malignant potential (M-UMP), mucinous 
neoplasm of low malignant potential (M-LMP), and mucinous carcinoma. They 
considered mucinous adenoma lesions, which involve appendiceal mucosal surface and 
are composed of mucin-rich epithelium. Cytological atypia is mild or moderate. There 
is no invasion by the epithelium into the muscular wall nor is there a presence of 
epithelium on the serosa. According to Pai and Longacre’s definition, mucinous 
adenoma is restricted to those cases without epithelium involvement in extra-
appendiceal mucin. Consequently, if the appendix is surgically excised, no further 
treatment is required. In the case of M-LMP, however, neoplastic cells are sprayed 
beyond the appendix. Microscopic investigation does not reveal any significant 
difference in individual cells between mucinous adenoma and M-LMP. Therefore, the 
15 
 
differential diagnostics between these two groups is challenging. It is impossible to 
definitely exclude the possibility of extra-appendiceal spread of epithelial cells, even if 
no macroscopic tumour can be seen on the peritoneal surfaces. The group that falls 
between M-LMP and mucinous adenoma, was designated M-UMP by Pai and 
Longacre. They also restricted the use of this category to those cases with extremely 
well-differentiated mucinous neoplasms but which also had an uncertain stage of 
invasion. In contrast, mucinous carcinoma exhibits architectural complexity and high-
grade cytological atypia with high mitotic activity. Destructive invasion is seen in most 
cases, if not all. The borders between mucinous adenoma, M-UMP, and M-LMP are 
rather indistinct. There is always uncertainty as to whether the epithelial cells have 
sprayed on peritoneal surfaces, thus the division of histological comparably 
homogeneous group of lesions by invasiveness might be somewhat irrelevant. On the 
other hand, a clear dividing line can be drawn between the mucinous carcinoma and the 
other groups.  
 
The WHO 2010 classification [19] of pseudomyxoma peritonei is straightforward and 
rather similar to that of the Bradley group’s classification [19]. The lesion can be 
classified according to the definition as low-grade or high-grade pseudomyxoma. The 
alternative terms low-grade and high-grade mucinous adenocarcinoma can be used as 
well. The WHO avoides the use of the term DPAM, since the concept of ruptured 
adenoma can be seen as an understatement for a condition that commonly is lethal. The 
primary appendiceal lesions are classified as low-grade appendiceal mucinous neoplasm 
(LAMN) or mucinous adenocarcinoma. For the previously mentioned reason, the WHO 
avoided the use of term adenoma in case of LAMN as well. Principally, LAMN is 
related to low-grade PMP, whereas mucinous adenocarcinoma is related to high-grade 
PMP. 
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PMP is currently regarded as a condition that is derived from the appendix at least in the 
vast majority of cases [11, 22]. Synchronous ovarian lesions are frequently seen in 
female patients, which has led to confusion about the true origin of PMP [23]. There are 
histopathological, immunochemical, and molecular genetic studies that suggest the 
appendix as an origin in those cases with synchronous tumour of appendix and ovary 
[10, 22, 24]. Most cases of PMP showed positive expression for cytokeratins (CK) 18 
and 20 when immunohistochemical expression was tested whereas the reaction was 
mostly negative for CK 7.  The expression of human alveolar macrophage (HAM) 56 
tended to be negative and that of carcinoembryonic antigen CEA positive. Thus, the 
pattern of immunoreactivity was distinct from primary ovarian tumour and similar to 
appendiceal adenoma [22]. The PMP cases demonstrated identical K-ras mutations in 
appendiceal adenoma and corresponding synchronous ovarian tumour when K-ras 
mutations were identified. The loss of heterozygosity (LOH) was observed in the 
ovarian tumour when the LOH on specific chromosomes was examined, whereas both 
alleles were retained in the matched appendiceal lesion in most cases. This finding 
supports the conclusion that ovarian lesions are metastatic [10]. 
The abundant expression of the MUC2 and MUC5AC genes were determined by both 
immunohistochemistry and in situ hybridization when O´Connell et al. studied gene 
expression of PMP cases [25]. The expression of MUC-2, in particular, explains the 
copious amounts of extracellular mucin found in PMP. Appendiceal goblet cells express 
both MUC2 and MUC5AC, but mesothelial cells and the cells of the ovarian surface 
express only MUC5AC. This gene expression pattern suggests that PMP is of 
appendiceal origin and not of ovarian or mesothelial origin. The cases of PMP were also 
compared to the control cases with normal appendix and in situ hybridization studies 
obtained strong MUC2 and MUC5AC signals both in PMP cells and goblet cells of the 
normal appendix. Nongoblet cells of the appendix showed no MUC2 signal. This 
finding suggests that the goblet cells of the appendix are the origin of PMP. 
There are several studies that report a non-appendiceal origin of PMP. For example, 
PMPs that arise from mature cystic teratoma, pancreas, urachus, and colon in addition 
18 
to ovaries have been reported [26-28].  Therefore, PMP is not synonymous with 
appendiceal neoplasm with peritoneal spread, even though the appendix can be 
generally identified as the site of origin. 
??????????????????????????
The clinical manifestations of PMP are manifold. The classic sign is increased 
abdominal girdle, which is caused by the accumulation of gelatinous ascites. The 
disease may sometimes be presented as “jelly belly” at the time of diagnosis. This is 
characteristic of the progressive state of disease in which the most of the abdomen is 
filled with ascites and tumour [23]. The chief complaint may be a newly-onset hernia as 
a consequence of increased intra-abdominal pressure. The abundant tumour may 
sometimes cause intestinal obstruction. Appendicitis may be the first manifestation of 
PMP. PMP lesions may also cause pain in the flank(s) due to obstruction of the ureter. 
Mucinous ascites may flow into the scrotum mimicking hydrocele. A large proportion 
of diagnoses are established co-incidentally: ultrasonography or CT-scan performed for 
any reason may reveal PMP. A typical finding is an ovarian mass found by transvaginal 
ultrasonography during routine gynaecological examination. During surgery, there 
might be unexpected deposits of mucus on the peritoneal surfaces. 
19 
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The gold standard for imaging PMP is computed tomography (CT), preferably with a 
contrast medium [29-31]. A CT may identify appendiceal mucocele in the early stage of 
the disease that can often be calcified and accompanied by mucus in the ileocaecal 
region. Progressing PMP is characterized by visceral and mesenteric sparing. Gastric 
antrum, lesser omentum, left subphrenic region, spleen, rectum and sigma are entangled 
by the tumour mass in the terminal stage of the disease. The primary tumour is rarely 
seen in the appendix at this stage. What is emblematic for the terminal stage is the 
aforementioned scalloping of the hepatic margin, and a displacement or compression of 
the intestines by the abundant mucus [23]. 
There are reports of the usefulness of ultrasound in the diagnosis of PMP [32, 33]. 
Echogenic ascites reflect the gelatinous nature of the fluid. The ascites is not mobile. 
Bowel loops are positioned centrally and posteriorly by the surrounding mass instead of 
floating freely. There may be a septated appearance to the ascites. Scalloping of the 
hepatic margin may be present in PMP, although other conditions that cause peritoneal 
spread may also induce this effect [32, 34]. Some authors have noted ultrasonography to 
be more beneficial for guide paracentesis [30]. The needle biopsies commonly produce 
less information than expected when no mucus or no cells within the mucus are 
aspirated. The quantity of epithelial cells within the mucus may be low even in high-
grade disease, thus the final evaluation about the grade should not be made from biopsy 
alone [23]. 
The role of colonoscopy in the diagnosis of PMP is minimal. Tumours of the appendix 
are infrequently seen in colonoscopy and rarely yield a diagnostic biopsy [35]. 
20 
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Circulating tumour markers have a prognostic value in PMP. They are also useful 
instruments in follow-up after surgery. 
Koh et al. reported that the elevation of carbohydrate antigen 19-9 (CA 19-9) was 
negatively associated with OS in patients with the DPAM subtype of PMP [36]. Not 
only did the marker manifest positivity above the laboratory reference range (>40 
U/mL), the absolute level of CA 19-9 was also prognostically significant. The 
prognostic value of CA 19-9 was not noted in the PMCA group of the same study. Van 
Ruth et al. have suggested CA 19-9 to be a more useful tumour marker than CEA for 
follow-up [37]. Those authors also noted that patients who never attained normal CA 
19-9 levels after surgery were more prone to recurrence of the disease at 1 year (53% vs 
15%). 
Canbay et al. noted that elevated carcinoembryonic antigen (CEA) levels measured 
preoperatively associated with the peritoneal cancer index (PCI, Heading 5.2.4.3), with 
cytoreductive surgery scores, with progress free survival and with OS [38]. Moreover, 
Alexander-Sefre et al. noted that CEA was the most commonly elevated tumour marker 
in PMP, which was contrary to that suggested about the usefulness of CA 19-9 [39]. 
Those authors also noted that elevated CEA prior to complete tumour removal predicted 
early recurrence. The 2-year recurrence free interval in those with elevated and normal 
CEA, were 53% and 94%, respectively. 
Taflampas et al. analyzed the elevation of preoperative serum marker levels of CEA, 
CA19-9, and CA12-5 in a study with a population of 519 patients [40]. The patients 
with normal marker levels (131/519) had significantly higher mean disease-free (DFS) 
and OS than those who had elevated levels of all three markers (109/519). The mean 
DFS and OS figures were 168 months and 125 months for patients with normal markers 
versus 65 months and 55 months for patients with all three markers elevated. 
21 
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Some authors of an early study had suggested follow-up only, without surgery, for 
PMP, but this former approach did not achieve wide acceptance [9]. Systemic 
chemotherapy (SC) alone has generally not been considered useful in PMP, because 
therapeutic levels of cytostatic agents are hard to attain in tumour cells surrounded by 
mucin accumulations [23, 41-43]. Surgical debulking has traditionally been the standard 
approach for patients with PMP [44, 45]. The debulking protocol is consisted for the 
surgical removal of gross disease. Complete radicality is uncommon, however, and 
relapses will develop in most cases. The relapses lead to increasingly difficult 
subsequent operations, after adhesions, scarring, and distortion of the anatomy has 
developed and the disease has progressed. The timing of iterative operations is driven 
mostly by symptoms. In the end, further surgery is impossible. The short-term results 
are rather favourable with 53% - 85% OS at 5-year follow up [44, 45]. However, the 10-
year OS figures are more modest with survival rate of 21% - 32% [44, 45]. 
?????????????????????????????????????
The peritonectomy procedures, as originally described by Sugarbaker, consist of six 
different resections that are used to remove the tumor from peritoneal surfaces [46]. 
These resections are as follows: greater omentectomy-splenectomy, left upper quadrant 
peritonectomy, right upper quadrant peritonectomy, lesser omentectomy-
cholecystectomy with stripping of the omental bursa, pelvic peritonectomy with sleeve 
resection of the sigmoid colon, and antrectomy. These procedures are used on every 
single patient to an extent that is sufficient for the removal of the tumour. (Figures 1–5). 
During the operation, the extent of the disease and the radicality of the surgery is 
assessed and scored. The scoring systems are reported in detail (5.2.4). There are typical 
situations, when radical surgery is technically impossible. Indeed, tumour burden 
locating in the hepatic hilum or in the lesser omentum can be surgically unresectable. 
The extensively disseminated disease in the abdominal cavity that especially affects the 
small intestine may prevent radical surgery. Surgery with a radical end-result is a 
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fundamental part of successful combined therapy, as it is a prerequisite for the 
administration of HIPEC in most cases. If the tumour is not completely resected from 
the abdominal cavity during the cytoreductive surgery, the chemotherapeutic agent will 
not eliminate the disease. The cytoreduction is considered complete when residual 
tumour nodules are sized under 0.25cm at the most. 
The current practice includes complete cytoreductive surgery to be followed by HIPEC. 
To the best of my knowledge, only one series about complete cytoreductive surgery 
without HIPEC has been published [47]. This retrospective series that emanated from 
New Zealand included 25 patients with PMP. The 5-year overall survival (OS) was 64% 
for the study population. The OS was 92% for those with DPAM pathology and 33% 
for those with PMCA. 
?????? ?????
Intraoperative HIPEC was initiated at the Washington Hospital Center in 1992 [48]. The 
administration of a chemotherapeutic agent is timed after complete cytoreductive 
surgery is finished but before the construction of any anastomoses. Perfusion drains are 
placed through the abdominal wall at specific sites: the right subdiaphagmatic space, the 
left subdiaphagmatic space, and two in the pelvis (Figure 6). One additional spiral-
ended (Tenckhoff) catheter is positioned within the abdomen. The Coliseum technique 
involves the elevation of the edges of the abdominal incision onto the self-retaining 
retractor by a running suture. A plastic sheet is then sewed to that suture and a cavity for 
chemotherapy is consequently formed. An incision in the plastic sheet is made and a 
portal is then attached, which allows manual access into the cavity (Figure 7). The 
perfusion is then performed for 90 min (Figure 8) and the surgeon secures the 
distribution of chemotherapeutic agent manually during that time. The 
chemotherapeutic agent used in the original setting was mitomycin C (MMC), as 
reported by Sugarbaker and his co-workers. The target temperature of the 
intraperitoneal fluid is 41°C to 42°C. There are at least three reasons, why 
chemotherapy solution should be heated: the tissue penetration of the 
chemotherapeutics is increased, the cytotoxicity of the chemotherapeutics is increased, 
and also because of the inherent anti-tumour effect of heat itself [49].  The manual 
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distribution of chemotherapeutic agent for 90 minutes affords several advantages: all 
surfaces of the abdomen and pelvis are uniformly affected by the chemotherapeutic 
agent and heat, diuresis can easily be monitored during the administration of agents that 
can affect renal functioning, hyperthermic therapy lasting 90 minutes causes mechanical 
disruption of cancer cells within blood clots and fibrin accumulations, and the 
moderately long time allows the normalization of many physiological parameters 
(temperature, haemodynamics, coagulation, etc.) [49]. 
Elias et al. have reported other chemotherapeutic regimens for HIPEC than that 
originally described by Sugarbaker [50, 51]. For instance, Elias et al. described the use 
of oxaliplatin instead of MMC in different regimens. Intraperitoneal oxaliplatin was 
administered either alone, in combination with intraperitoneal irinotecan, or after 
administration of intravenous 5-fluorouracil (5-FU) with leucovorin. The 5-FU is 
assumed to potentiate the activity of oxaliplatin. The 5-FU and oxaliplatin cannot be 
administered simultaneously within the abdominal cavity because of the pH 
incompatibility. Thus, 5-FU is administered intravenously. The target temperature of 
HIPEC in their protocol was 43°C and the duration was 30 minutes. The cytotoxicity of 
various drugs for PMP cells was tested in vitro [52]. Those findings suggested a 
combination of cisplatin and doxorubicin for treating PMP. These results encouraged 
Andréasson et al. to perform HIPEC treatment for some patients using the combination 
of cisplatin and doxorubicin over 90 minutes [53]. 
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High rates of complications have been reported after the administration of CRS and 
HIPEC [53-60]. Non-surgical complications include inter alia neutropenia, sepsis, 
pleural effusion, respiratory insufficiency, and thromboembolism. Surgical 
complications include anastomotic leakage, bowel perforation, haemorrhage, fistula 
formation, bile leakage, abscess formation, and wound dehiscence. The complication 
rates of some studies are enlisted in table 2. 
 
Sugarbaker et al. reported a series of 356 procedures with CRS and HIPEC [61].  In that 
series, grade IV adverse events occurred in 67 (19%) of the procedures. The distribution 
of those complications was as follows: haematological 28%, gastrointestinal 26%, 
cardiovascular 16%, pulmonary 9%, genitourinary 8%, infections 5%, neurological 4%, 
and IV catheter 4%. Events that resulted in a return to the operating room were recorded 
for 40 (11%) of the procedures. The distribution of causes for return to the operating 
room was as follows: fistula 29%, anastomotic leak 19%, compartment syndrome 19%, 
postoperative bleeding 18%, pancreatitis 3%, bile leak 3%, fascitis 3%, urine leak 3%, 
and negative exploration 3%. 
 
Thromboembolisms are featured complications in HIPEC [57]. Not only are deep 
venous thromboses encountered, pulmonary embolisms and portal vein embolisms also 
occur. Special attention should be paid to anti-thrombotic treatment during the 
perioperative course. The wearing of anti-embolic pump stockings in combination with 
intensified low-molecular weight heparin are offered with the purposes of avoiding such 
complications.  
 
Neutropenia frequently follows HIPEC [62]. Intraperitoneal chemotherapy with MMC 
causes less toxicity than systemic administration. Even so, a 39% incidence of 
neutropenia was reported after such therapy by Lambert and co-workers in 2009 [62]. 
Those authors also noted that female gender and MMC dose per surface area were 
independent risk factors for MMC-induced neutropenia. Despite this, neutropenia was 
not found to be associated with an increased risk of operative mortality or increased 
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hospital stay. The only infection type neutropenia was associated with was urinary tract 
infection, but no other types were associated with neutropenia upon univariate analysis. 
 
Anastomotic leak represents a typical gastrointestinal complication after CRS and 
HIPEC combined treatment, which results in a substantial portion of cases requiring re-
operation [61]. The construction of any anastomoses is postponed till after the 
intraperitoneal chemotherapy has finished in order to avoid these complications. Hand-
sewn seams are preferred over stapled seams. 
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The benefit of SC in patients with PMP is unknown because no prospective trials have 
been published [63]. The data concerning SC are discordant. Two rather old reports 
found the use of SC was not beneficial when used in conjunction with debulking 
surgery. Gough et al. reported that the use of SC had an adverse effect on OS in 56 
patients treated by debulking surgery, radiation and/or chemotherapy upon analysis by a 
Cox model [44]. Smith et al. found no difference in survival rates between the patients 
who received operative treatment only and those who received postoperative SC in a 
series of 17 patients who had undergone palliative debulking surgery for PMP of 
appendiceal origin [43]. It is notable that the SC was delivered by very heterogeneous 
regimens within both these studies and some of the patients also received intraperitoneal 
chemotherapy. One of the largest retrospective reports about SC was obtained from a 
multicenter international study of 2298 patients with PMP of which 2054 had been 
treated by CRS and HIPEC [64]. SC was administered to 377 patients before the 
cytoreduction. They found that earlier chemotherapy treatment was an independent 
predictor of poorer progression-free survival (PFS) and OS as analyzed by the Cox 
model. Contrary to those reports of no or negative effect of SC, there are studies that 
report some benefit from SC. Shapiro et al. reported a series of 186 patients who were 
considered ineligible for CRS and/or HIPEC [65]. They noted a disease control rate of 
56% with modern SC regimens. The authors of that study concluded that SC may have 
a role in a patient population that comprises suboptimal candidates for CRS and HIPEC, 
although they recognized a need for randomized trials. Farquharson et al. revealed that 
38% of patients with advanced unresectable PMP benefited from SC as indicated by a 
reduction in mucinous ascites or a stabilizing disease [66]. Blackham et al. studied the 
role of SC in conjunction with CRS with HIPEC [63]. Postoperative SC seemed to 
improve PFS in patients with high-grade PMP treated by CRS and HIPEC in 
comparison with CRS and HIPEC alone (13.6 months vs. 7.0 months, P=0.03) and also 
in comparison with pre-operative SC (13.6 months vs. 6.8 months, P<0.01). On the 
other hand, the Blackham group’s results did not support the routine use of 
perioperative SC in low-grade PMP (Median OS 107 months vs. 72 months, P=0.47). 
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In conclusion, there is limited evidence that SC is beneficial in advanced inoperable 
PMP and in high-grade PMP. Even so, the duration of SC and the preferable pattern in 
addition to the specific medication need further investigation. A randomized double 
blind trial would be optimal to meet this aim. 
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The results of some of the main studies regarding the CRS and HIPEC combined 
treatment published since 2005 are summarized in table 3. The main treatment protocol 
is generally rather similar in all the centers that provide HIPEC. Even so, there are 
specific differences in chemotherapy protocol, histological classification of the tumour, 
follow-up time, reporting of the surgical completeness, and so forth. Some centers only 
provide HIPEC for patients after complete cytoreduction [50]. Other centers proceed 
with HIPEC after complete and sometimes also after incomplete cytoreduction [53]. 
Some studies reported only for those patients with complete CRS followed by HIPEC. 
When only those cases that are successfully treated by HIPEC are reported and those 
with incomplete CRS are excluded, the results become biased. First, the results of the 
studies include only the successful cases are not comparable with those studies that also 
include cases with non-radical CRS. Second, when only successful cases are reported, 
the outcome of the CRS and HIPEC combined treatment are exaggerated.  
 
The poorest outcome for 5-year OS shown in table 3 was obtained from a small German 
series that also included patients with non-radical CRS [60]. All 28 patients in the series 
received HIPEC. The study is not only the smallest series in the compared 
investigations, it is also the oldest and thus represents the early era of combined 
modality treatment. The best outcome was obtained from the Italian series of 53 
patients, who underwent radical surgery combined with HIPEC [55]. The 10-year OS in 
that series was as high as 84.5%. A minority of the studies report 10-year OS figures, 
whereas the majority of studies report 5-year OS. The survival outcomes are not fully 
comparable because of the heterogeneity of the patient populations. Despite the lack of 
uniformity in the patient demographics of the different series, the conclusion of the 
comparison is clear. The survival rate is excellent for those patients who were able to 
undergo complete CRS and HIPEC combined treatments.  
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There are certain aspects that still require attention. There are a limited number of 
studies with a follow-up that exceeds 10 years. The natural progression of PMP is slow 
and consequently the true efficacy of HIPEC is only likely to emerge after a long 
follow-up time. The survival of patients treated by serial debulking may sometimes be 
rather favourable as well. Therefore, the debate on the efficacy of using HIPEC should 
still be continued. The long-term results of HIPEC must be widely evaluated. The whole 
patient population includes patients who are ineligible for HIPEC and who also should 
be included in that analysis. Only after such a critical and comprehensive analysis, 
would it be possible to draw valid conclusions about the efficacy of HIPEC. It is 
presumed that the CRS and HIPEC combined treatment can withstand the most critical 
evaluation when treating patients with PMP. 
There were reports of several affecting factors upon analyzing the outcome in patients 
with PMP in detail. The extent of the disease is obviously a factor that has impact on the 
treatment. Elias et al. reported, that a PCI over 24 had a significant impact on the 
disease-free survival [50]. A high PCI value was found to be an independent factor for a 
poorer PFS in a large multi-center study reported by Chua et al. [64]. Smeenk et al. 
noted that the affected regions associated with decreased disease-specific survival 
(DSS) probability were the left subdiaphragmatic region and the subhepatic region [41]. 
In the case of tumour lesions that exceeded the size of 5cm and involved the small 
bowel, the DSS was affected. The histopathological grade of the tumour has also been 
reported to affect survival in many studies [20, 64, 67]. Dayal et al. reported that tumour 
morphology of a high grade was an independent negative prognostic factor as indicated 
by multivariate analysis [68]. The large multi-center study reported by Chua et al. 
showed that the histological subtype of PMCA was an independent predictor for a 
poorer outcome for both PFS and OS as evaluated by multivariate analysis [64]. Strong 
evidence supports that the surgical result has an impact on survival. Andréasson et al. 
reported a comparison between 110 patients treated by cytoreductive surgery and 40 
patients treated by debulking surgery [53]. In that study, they adjusted for the following 
prognostic factors: sex, histopathology, PCI, Prior Surgical Score, type of surgery, 
intraperitoneal chemotherapy regimen, and surgical outcome. Those authors used a Cox 
proportional hazard model and found that only the surgical outcome had an impact on 
survival. The multi-center study reported by Chua et al. indicated that incomplete 
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cytoreduction (CC-2 or CC-3) was an independent predictor for poorer outcome for 
both PFS and OS in multivariate analysis [64]. Dayal et al. demonstrated a 10-year OS 
of 64% for patients who had undergone complete CRS in comparison with 22% for 
those who were maximally debulked [68]. Elevated serum tumour markers were found 
to have an effect on survival. Dayal et al. observed that elevated CA12-5 was a 
significant negative prognostic factor in univariate analysis [68]. Kusamura et al. 
documented that preoperative circulating tumour marker levels of CA12-5 > 125 U/mL 
and CA19-9 > 89 U/mL independently affected OS using a multivariate analysis Cox 
model [69]. Moreover, elevated preoperative CEA levels have been found to affect OS. 
in the Cox model reported by Canbay et al. On the other hand, elevated CA12-5 and 
synchronous elevation of all three markers of CA12-5, Ca19-9, and CEA were factors 
associated with early recurrence after HIPEC [70]. 
??????????????????????????????
To the best of my knowledge, hitherto no scientifically evaluated follow-up protocol 
after HIPEC for the patients with PMP has been published. It is obvious that patients 
with PMP should be followed-up after surgery for the progression or recurrence of the 
disease and associated conditions. The suggested methods for follow-up after surgical 
treatment include physical examination, CT, and determining serum tumour markers 
[23]. 
Physical examination may reveal new tumour deposits in the scars or the abdomen, 
abdominal distension, or newly-onset hernias. Patients may have abdominal complaints 
that are related to relapse or to disease progression. 
The natural choice for the imaging instrument is CT. First, it is considered the gold 
standard for imaging PMP and therefore it is also useful in follow-up. Second, 
practically every patient will have undergone CT prior to HIPEC. Consequently, there 
will be reference images stored to compare with during the follow-up. According to the 
consensus statement on the treatment of PMP, other imaging methods such as MRI, 
PET, or CT-PET have little or no value in follow-up after treatment [2]. PET provides 
limited value in the diagnostics of low-grade lesions, which is often the classification of 
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PMP [71]. MRI is more expensive and time consuming than CT. Some authors have 
suggested MRI, particularly for preoperative staging and classification purposes [72]. 
Pre-operative elevation of tumour markers is known to associate with an increased risk 
of recurrence and reduced survival after complete CRS [40].  The CEA and CA19-9 
markers seem to be especially useful for the detection of progression [23]. The elevation 
of tumour markers after surgery usually signifies activation of PMP. 
There is no definitive consensus on the timing of follow-up visits after surgery. A 
proposed starting point for further follow-up is three months after surgery, which 
includes CT, clinical examination, and serum tumour markers determinations. Follow-
up visits should be biannual in the first year and yearly in the subsequent years. In the 
case of a suspected relapse, the examinations should be immediately performed 
regardless of the protocol [23].  
In our center, the first follow-up visit is scheduled for three months after surgery, and it 
includes clinical examination and serum tumour markers (CEA, CA19-9). The second 
follow-up visit is at six months after surgery, and it includes clinical examination, serum 
tumour markers determination, and CT. The subsequent follow-up visits are repeated 
every six months for up to two years and they include the same examinations as for the 
six- month follow up visits. After two years follow visits are given annually. The total 
duration of the subsequent follow-up is considered individually for each patient and 
varies from five to ten years. Our aim is to optimize the balance with minimizing 
radiation, coping with hospital resources, and early detection of relapses. 
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Pseudomyxoma peritonei (PMP) is a clinical condition. The estimated incidence is 1-2 
per million annually. The abdominal cavity is progressively filled by ascites and 
mucinous tumour. The symptoms and signs of PMP may include: an increase of 
abdominal girdle, newly-onset hernia, vague abdominal complaints, flank pain, bowel 
obstruction symptoms, appendicitis, ovarian mass and hydrocele. Moreover, many cases 
are diagnosed co-incidentally. The tumour is derived from the appendiceal epithelium in 
the vast majority of cases, but other origins have also been reported in a minority of 
cases, including: PMP arising from mature cystic teratoma, pancreas, urachus, colon, 
and ovaries have been reported. Many histological classification schemes have been 
proposed. According to the WHO 2010 definition, the tumour can be classified as low 
grade and high grade. The tumour causes organ malfunctioning, mostly by compression 
as the disease progresses. The disease is best treated by surgery. The classic surgical 
approach was to debulk the tumour iteratively until further surgery becomes 
impracticable. The contemporary approach comprises radical cytoreductive surgrery 
(CRS). The CRS is immediately followed by hyperthermic intraperitoneal 
chemotherapy (HIPEC) during surgery. The CRS and HIPEC combined treatment was 
first introduced by Paul H. Sugarbaker from the Washington Cancer Institute. Improved 
survival has been reported for patients treated by CRS and HIPEC in combination. 
However, not all patients are eligible for combined CRS and HIPEC. If those patients 
who are not eligible for HIPEC are included in the analysis, then the survival outcome 
is not as good as it was when only the successful cases were included. Unbiased 
evaluation of the real benefits of the CRS and HIPEC combination is very important. 
The natural progression of PMP is slow, and the true efficacy of CRS and HIPEC 
combined is seen only after long-term follow-up. 
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The main purpose of the present study was to analyze the diagnosis and treatment of 
PMP. Specific aims were: 
1. To evaluate the outcome of patients with PMP that were treated by serial
debulking.
2. To explore the clinical manifestations of PMP that lead to a diagnosis.
3. To analyze the feasibility of CRS and HIPEC combined treatments in patients
with PMP.
4. To compare the outcome of serial debulking and CRS with HIPEC in
consecutive patients with PMP for two time periods.
???? ????????????? ???????
???????????????
The protocols for studies III and IV was approved by the Helsinki university Central 
Hospital (HUCH) ethics committee (permission number 265/13/03/02/2011). Studies I 
and II were performed as retrospective chart studies and therefore without the need for 
ethics committee approval. All patients studied had the clinical condition of PMP. They 
underwent surgery or consideration concerning surgery between 1984 and 2011 in 
Helsinki University Central Hospital. Study I included 33 consecutive patients treated 
by the classic approach of serial debulking between the years 1984 and 2008. They all 
underwent surgery in our unit. Study II consisted of a consecutive series of 82 patients 
with PMP. The clinical presentation of PMP of those patients was analyzed. The patient 
population in study III comprised 90 patients who underwent consideration for CRS and 
HIPEC. Of those 90 patients, 87 were also included in study IV. The outcome of the 
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treatment was also analyzed in study IV. The outcome was then compared with the 
patient population of study I. The specific patient characteristics of studies I – IV are 
presented in table 4.
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PMP is a clinical entity. The diagnosis of PMP in this study was based on operative 
findings, pathological sampling, and radiological investigations. The initial diagnostics 
were performed either in our unit or in referral units.  
Histological samples were not reviewed, but the original pathological assessments were 
used in studies I and II. We performed a re-assessment for pathological samples for the 
patient population in studies III and IV. The cases were re-assessed using WHO 2010 
criteria for classification. Cases with diagnoses other than PMP of appendiceal origin 
were excluded. The other origins for peritoneal carcinomatoses found in the re-
assessment were: mixed adenoneuroendocrine carcinoma of appendix (MANEC), 
ovary, colon/rectum, ileum, and unknown. Those patients with malignant peritoneal 
mesothelioma and benign cystic mesothelioma were also excluded. 
????????????????
Repeated interval debulking was the standard treatment protocol for patients with PMP 
(I, IV) before the adoption of the combination treatment of complete cytoreductive 
surgery followed by HIPEC. Complete tumour resection was the aim, particularly in the 
initial surgery, but only for those cases for which the disease was amenable for that 
procedure. The successive surgeries were performed, when the symptoms necessitated. 
The peritonectomy procedures were not notably performed. Maximal debulking surgery 
was also offered to those patients in the HIPEC era who were excluded from CRS 
preoperatively or who had undergone a non-radical attempt at CRS (III, IV). 
The first patient received complete CRS followed by HIPEC combination for PMP in 
January 2008 (IV). After adopting HIPEC, every patient with demonstrable PMP were 
evaluated and considered for CRS and HIPEC combined (III, IV). When no medical or 
surgical contraindications were observed, an attempt at CRS to be followed by HIPEC 
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was scheduled (III, IV). Medical contraindications for CRS with HIPEC were poor 
overall status, severe co-morbidities, and, in limited cases, advanced age. The surgical 
contraindication that prevented an attempt at CRS with HIPEC was an extensively 
disseminated disease without any realistic probability for complete CRS upon 
examination by either radiological investigations or during prior surgeries. 
The HIPEC was administered only after complete cytoreduction was achieved (III, IV). 
The chemotherapeutic agent was MMC at the standard dosage of 30mg/m . A modified 
version of the Coliseum technique was used for administering the chemotherapeutic 
solution [48]. The target temperature of intraperitoneal solution was 42 - 43ºC and the 
duration was for 90 minutes. SC was not routinely used prior to or after HIPEC. Only a 
limited number of selected cases with non-radical surgery or with relapsed PMP 
received SCs. 
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Postoperative complications during the hospital stay were recorded and graded in study 
IV for those patients who had undergone surgery. The grading was performed according 
to the Clavien-Dindo classification of surgical complications published by Dindo et al. 
[73]. The streamlined classification is as follows:  
- Grade I refers to any deviation from the normal postoperative course that does not 
need intervention.  
- Grade II refers to complications requiring pharmacological treatment.  
- Grade III refers to complications that require surgical, endoscopic or radiological 
intervention.  
- Grade IV refers to life-threatening complications; and  
- Grade V refers to a death of a patient.  
When the patient had several complications, the most severe complication was reported. 
 
?????????????????????????????????????????????????????????
The radicality of cytoreductive surgery was assessed for those patients who underwent 
surgery with an intention of radical operation in studies III and IV. The radicality of 
surgery can obviously be scored only after an effort of cytoreductive surgery has been 
made. Our scoring was based on previously published cytoreduction scores [74]. The 
scoring was as follows: CC-0 signified that no visible tumour remained; CC-1 signified 
that tumours under 0.25 cm remained; CC-2 signified that tumours between 0.25 and 
2.5 cm remained; CC-3 signifies that tumours over 2.5 cm remained. The scores CC-0 
and CC-1 were further classified as radical and the scores CC-2 and CC-3 as non-
radical. 
 
46 
??????????????????????????????????????????
The peritoneal cancer index was used to assess those patients who underwent an attempt 
at CRS and HIPEC in studies III and IV. The index was determined intraoperatively 
after exploration of the abdomen and pelvis [75]. The abdominopelvic area is divided 
into 13 regions that are numbered from 0 to 12. The presence or absence of tumour 
nodules in each of the 13 regions were determined. The size of the lesion in each region 
was also assessed. The lesion size was scored from 0 to 3: 0 indicated no visible 
tumour; 1 indicated nodules less than 0.5 cm; 2 indicated nodules between 0.5 and 5 
cm; and 3 indicated tumour nodules over 5 cm. The summation of scores of each region 
resulted in the final PCI score. Thus, the maximum would be 39 (13 x 3). 
??????????
???????????????
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?????????????????????????????
The overall survival was analyzed according to the Kaplan-Meir survivorship method (I, 
IV). The end point was the death of a patient. The comparisons between the survival 
curves were assessed by a log-rank test (IV). The distribution of genders was tested by 
one-????????? ??? ????? ?????? ???????????????? ??????????? ????? ??????????? ???EC 
????????????????????????????????????????????????????????????????????????????????????? in 
addition to the proportion of patients with no-evidence of disease (IV). The comparison 
of populations was performed by Mann-Whitney U-test in the case of a delay between 
the diagnosis and assessment (III), in the case of a number of re-operations (IV) and the 
Student’s t-test was used to compare means for PCI and age (III). The test for 
comparison of the means was chosen according to the Kolmogorov-Smirnov test of 
normality (III, IV). The 30-d mortality after the initial operation was tested by using the 
Fisher´s exact test (IV). 
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????????????
??????????????????????????????????????????????
A consecutive series of 33 patients with PMP underwent a total of 113 operations. The 
study did not include patients who had non-surgical treatment only. The mean number 
of operations per patient was 3.4 (range 1 – 10). Re-operation resulting from a major 
complication occurred for 3/113 surgeries. Those re-operations were indicated for 
haemorrhage within the abdominal cavity, anastomotic leakage, and dehiscence of the 
surgical wound. No postoperative deaths were recorded after the initial operation. The 
30-d operative mortality for all 113 operations was 2.7% (3/113). Those three deaths 
respectively occurred in the terminal phase of PMP after the 3rd, 4th, and 8th operation. 
The 5- and 10-year OS rates were 67% and 31%, respectively. At the completion of the 
follow-up in study I, there seemed to be four patients with no evidence of disease. 
??????????????? ???????????????????
Clinical presentation of PMP at the first appointment was recorded and grouped for 82 
consecutive patients. The sex distribution was: 53 women (65%) and 29 men (35%). 
The groupings for symptoms and signs were (Table 1 in study II): abdominal pain (19 
patients); acute abdomen (17 patients); newly onset hernia (10 patients); increased 
abdominal girth (14 patients); coincidental diagnosis (11 patients); and other (11 
patients). The presumed diagnoses of the 82 patients prior to initial surgery were 
recorded. Suspected PMP was the cause for the initial operation in 23/82 cases (28%) 
and formed the most common indication for surgery among men with 13 of 29 cases 
(45%). Suspected ovarian tumour was the most common cause for surgery in females 
and accounted for nearly half 26/53 (49%) of the cases. Thirty-five patients underwent a 
CT-scan, of which PMP was demonstrable in 18 cases (51%). 
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????????????????????????? ???????????
A prospective series of 90 patients was offered HIPEC when feasible. HIPEC was 
successfully delivered to 56 of 90 patients (62%). An attempt at HIPEC was performed 
on 69 patients (77%), conventional surgery without an attempt at HIPEC was delivered 
to 11 patients, and 10 patients were referred back or transferred to palliative care 
without surgery. A radical end-result was achieved in four of those 10 cases who had 
received conventional surgery. 
Low-grade tumour morphology (P=0.013), age under 65 years (P=0.004), and 
preoperative serum carcinoembryonic antigen (CEA) level under 5.0μg/L (P=0.003) 
were associated with successfully delivered HIPEC. Mean PCI was lower (18.9 vs. 
32.6, p < 0.001) and age was younger (54.3 years vs. 61.6 years, p = 0.003) in patients 
who underwent successful HIPEC than for those patients who did not. No gender-
related effect was detected. The mean delay between the diagnosis and the treatment 
decision was longer among patients who were treated by other methods than HIPEC, 
although the difference was not statistically significant (24.1 months vs. 18.3 months, 
P=0.124). 
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????????????????????????????????????????? ??????????
The HIPEC-era group consisted of 87 patients who were offered HIPEC when feasible 
after the adoption of HIPEC as a treatment for PMP in Helsinki University Central 
Hospital in 2008. The control group of 33 patients that were treated by serial debulking 
was formed before the HIPEC era began. 
 
Of 87 patients, 56 received HIPEC, 12 were treated non-radically while attempting 
HIPEC, 9 were debulked, and 10 were referred back or transferred to palliative care 
without surgery. The 33 patients in the control group were treated uniformly by serial 
debulking. The results after treatment are represented in table 5. 
 
There was no difference in 5-year OS between the debulking-era group and the HIPEC-
era group. The mean number of re-operations was lower for the HIPEC-era group (1.6 
vs. 0.8, P=0.01). There were more patients who subsequently seemed to present with no 
evidence of disease in the HIPEC-era group than in the debulking-era group (54% vs. 
24%, P<0.01), although the follow-up time was shorter for the HIPEC-era group. The 
30-day operative mortality rates were low for both groups and no statistically significant 
difference was found (2.6% vs. 0%, P=1.0). Two patients died after the initial operation 
in the HIPEC-era group. Of these, one patient died of peritonitis after debulking 
surgery, whereas the other died of multi-organ-failure after receiving CRS with HIPEC. 
 
It is remarkable that the number of patients who presented with no evidence of disease 
at completion of follow up in the debulking-era group was higher in the updated data 
(IV) than in the original data (I) (8/33 vs. 4/33, P<0.01). This is possibly because in 
those cases with altered status, the radical surgical result may have not been achieved in 
the initial operation but only after subsequent operation(s) that took place after the 
completion of study I. 
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???? ?????????
?????? ???????????????????????????????????????????????
The diagnosis of PMP is difficult. The clinical symptoms and signs of PMP are varied 
and are commonly preoperatively misdiagnosed as other conditions (II). Sometimes the 
diagnosis is definite only after pathological assessment and even then a definitive 
diagnosis may still be challenging for the pathologist. According to our unpublished 
data, a substantial portion of cases with PMP had their classification altered when the 
grading was systematically reviewed. 
Abdominal pain was the most common symptom of PMP in our study (II). The 
diagnosis of acute appendicitis before the initial operation was suspected in 9% of the 
cases. As many as 49% of the female patients underwent their initial operation for a 
suspicion of ovarian tumour. In the series reported by Esquivel and Sugarbaker, 
suspected appendicitis was the most common presentation and it accounted for 27% of 
the cases [13]. Those authors also noted that 44% of the women in their study had their 
diagnosis of PMP confirmed while being evaluated for an ovarian mass. 
There are some particular problems in the diagnostics of PMP. The diagnosis is 
sometimes established only after pathological assessment and not pre- or intra-
operatively. In such cases, the intra-operative staging of the disease may have been done 
inadequately. When a surgeon thinks he is operating on a patient with an acute 
appendicitis, he is not likely to perform a staging laparotomy routinely. The accuracy of 
CT is limited in revealing small tumour deposits on the peritoneal surfaces (II), 
therefore a 2nd-look laparoscopy for staging purpose is sometimes a good option. This 
especially applies to those cases for which serum tumour markers are elevated after the 
surgery and the result of CT-scan is normal. What has to be remembered is that even 
negative diagnostic laparoscopy is not definite because a small lesion can still exist 
undetected within the abdominal cavity. Staging laparoscopy may also have a role in 
determining the feasibility of HIPEC. In particular, affluent tumour deposits of the 
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small intestine prevent HIPEC can be revealed by staging laparoscopy. It is probable 
that those patients with the high-grade disease, and thus a more invasive and aggressive 
disease, would benefit from a staging laparoscopy before an attempt at HIPEC [76]. The 
purpose of laparoscopy in such cases would then be to avoid unnecessary laparotomies, 
and on the other hand, enable necessary and timely HIPEC treatments. However, the 
abundant amounts of mucin that are often present may hinder the laparoscopic 
evaluation of the tumour load. Regardless of the method used, the preoperative 
assessment of the feasibility of HIPEC is difficult to achieve (III). The final success of 
complete cytoreduction is always evident only after an attempt at one has been carried 
out. 
?????? ?????????????????????????
Debulking surgery is a form of cytoreductive surgery, with the intention to reduce 
tumour bulk maximally. Sometimes, even a radical surgical result is achieved. Survival 
analysis in study I showed a 10-year OS rate of 31%. The survival data were updated, 
after five more years of follow-up, in study IV and the 10-year OS rate was found to be 
39%. This might suggest that more effort was focused on achieving maximal 
cytoreduction in the later cases of the series than in the earlier cases. The philosophy of 
treating patients with PMP has undergone a drastic change after adopting the complete 
cytoreductive surgery followed by HIPEC combination modality.  It is probable that the 
pursuit of maximal cytoreduction is still achieved in patients treated by debulking in the 
21?? century even though the surgical approach is not as aggressive as in it is for 
complete cytoreduction. 
Miner et al. reported a series of 97 patients with PMP that had been treated by function 
preserving debulking [45]. They achieved optimal cytoreduction in 55% of the cases. 
Even though, PMP recurred in 91% of cases and 10-year OS was 21%. As much as 90% 
of those patients who survived over 10 years had low-grade histology. Our 10-year OS 
rate of 39% is substantially more favourable than that reported in their study. The 
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proportion of patients who presented with no evidence at the completion of follow-up is 
also higher in our series (24% vs. 12%). 
The combination of cytoreductive surgery and HIPEC is presently considered as the 
treatment of choice for PMP [2]. The precise role of HIPEC in the combined modality 
treatment is actually unknown. Some authors stated that HIPEC has a particularly 
critical role in achieving long-term remission [77]. Patients treated successfully by 
combined modality treatment manage well, but as to what part of this is due to the 
optimal cytoreduction and what is due to HIPEC remains unclear. A study from New 
Zealand reported a 5-year survival rate of 64% in patients treated by CRS without 
HIPEC [47].  The outcome of such a study reporting a patient population treated by 
CRS alone without HIPEC could be compared with an investigation reporting patient 
population treated by CRS and HIPEC combined. A large multi-center study on 2298 
subjects, already cited under heading 4.8.4., reported 5-year OS of 74% for patients 
treated by CRS and HIPEC [64]. At first sight these two studies appear to be 
comparable. Unfortunately, unknown numbers of patients were excluded from both 
these studies. Patients treated by palliative debulking were excluded from the series 
from New Zealand, as were the patients whose disease was considered technically 
unresectable. Thus, upon closer inspection the survival results of the two studies are not 
fully comparable. The series from New Zealand about CRS without HIPEC is the only 
one that has been published to the best of my knowledge. Evidence from comparisons 
between CRS only treatment with that of the CRS and HIPEC combined treatment is 
very scarce. Indeed, a prospective comparison between CRS only and CRS with HIPEC 
combined would be the best way to clarify the effects of HIPEC. Such a comparison 
would be informative, but would raise ethical questions, because HIPEC is presumed to 
benefit patients with PMP. Nevertheless, patients who are not eligible for the combined 
modality treatment may still benefit from maximal debulking surgery [68]. We noted 
the rather favourable 5-year survival rate of 67% (IV) in debulked patients. Debulking is 
still an option in a proportion of patients who are ineligible for the combined modality 
treatment, because of medical contraindications or whose disease is technically 
unresectable. 
55 
?????????????? ????????????????????????
Although the CRS and HIPEC combined treatment is currently considered as the 
treatment of choice for patients with PMP, it is impracticable to deliver it to every 
patient with PMP. In our study (III), complete cytoreduction was achieved in 60 out of 
90 cases (67%) and HIPEC was successfully delivered to 56 (62%) patients with PMP. 
Ten patients (11%) were treated non-operatively, but all had had an earlier limited 
operation. A prospective database from Basingstoke England included 748 patients who 
underwent surgery for PMP [68]. The number of patients who did not undergo surgery 
was not reported. Complete cytoreduction was achieved in 543 (73%) cases and HIPEC 
was delivered in 448 (60%) cases. A large multi-center study on 2298 patients excluded 
an unknown number of patients who were deemed medically unfit to undergo radical 
surgery or whose disease was considered technically unresectable preoperatively [64]. 
Optimal cytoreduction (CC-0 or CC-1) was achieved in 1904 cases (83%). 
Intraperitoneal chemotherapy (HIPEC, EPIC or both) was administered in 2094 cases 
(91%). Therefore, a proportion of patients had not undergone complete CRS before 
receiving intraperitoneal chemotherapy. Consequently, the protocol of that study is 
fundamentally different from our protocol of delivering HIPEC only to patients after 
optimal CRS. A series from Uppsala included 152 patients who underwent surgery for 
PMP [53]. Two cases with “open and close” laparotomy were excluded. The number of 
excluded patients who were preoperatively considered unfit for surgical treatment was 
unknown, however. Cytoreduction with no macroscopic residual tumour was achieved 
in 79 patients (52%). 
The results of these studies are typical findings after delivering complete CRS. Some 
studies do not report the original number of patients who were preoperatively excluded 
or excluded even after an attempt at surgery. What must be emphasized is that in such 
studies, the accurate assessment of success of CRS remains undetermined. Whether or 
not the actual number is reported, there is the phenomenon that a substantial and similar 
portion of patients with PMP are not eligible for complete CRS in every study and in 
every situation.  The comparison of the rate of complete CRS delivered is difficult to 
ascertain between the centers. Health care systems are different. Some tertiary care 
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centers receive unselected referrals whereas the others accept only referrals of patients 
who have already been evaluated as fit for surgery. In some health care systems, 
debulking surgery may also be delivered in secondary care hospitals whereas tertiary 
care hospitals may have the sole responsibility for any attempt at delivering CRS and 
HIPEC. 
Our 5-year OS rate of 9?% for those who had undergone CRS and HIPEC is very good 
and fully comparable with the results of other centers. Three other European studies that 
included only patients with complete CRS are those reported by Vaira et al. from Italy, 
Iversen et al. from Denmark, and Youssef et al. from the UK [55-57] who reported 5-
year OS rates of 94%, 73%, and 87% respectively. There are also series published that 
show lower rates of complete cytoreduction and some of those reported more modest 
survival rates as well. Andreásson et al. reported a 5-year OS of 74% with 72% 
complete CRS rate, Kuijpers et al. reported a 5-year OS of 65% with 80% complete 
CRS rate, and Güner et al. reported a 5-year OS of 43% with 40% complete CRS rate 
[53, 54, 60]. One of the largest studies that reported 10-year OS rates is the international 
multi-center study published by Chua et al. who obtained a 10-year OS rate of 63% for 
2298 patients [55, 64]. One of the highest survival rates was reported by Vaira et al. 
who obtained a 10-year OS rate of 84.5% [55, 64]. 
We noted major complications (grade 3-5) in 47 (61%) for operated patients during the 
HIPEC-era (IV). The rate is considerably higher than the rate of 24% reported by Chua 
et al. [64]. Though, the most common complication in our study was pleural effusion, 
which resulted in 36 grade 3 complications. If those cases whose only complication was 
pleural effusion that can be relatively easily treated by punction were to have been 
excluded, the major complication rate would have been much more favourable. The 
high numbers of grade 3 complications found in the present study were categorized to 
the Clavien-Dindo classification system, which is rigorous for the pleural effusion 
complication. For example, Common Terminology Criteria for Adverse Events 
(CTCAE) V4.03 would have rated postoperative pleural effusion aspirated by 
radiologist as only a grade 2 complication. It should also be noted that the grade 4 
complication rate in our study was only 7.8%, whereas Chua et al. observed a grade 4 
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complication rate of 10% [64]. The postoperative mortality rate of 2.6% is acceptable, 
since only two postoperative deaths occurred during the HIPEC-era of which one was 
recorded after CRS and HIPEC combined treatment and the other after debulking 
surgery alone. Chua et al. observed a comparable postoperative mortality rate of 2% 
[64].  
???????????????????????????? ?????????
When the whole population of patients with PMP was included in the analysis, there 
was no difference in short-term survival between the serial debulking method and CRS 
and HIPEC combined treatment. When only those patients who had received both CRS 
and HIPEC, are included in the analysis, the survival benefit is evident even after the 
rather short follow-up of five years. It is possible that given the slow progression of the 
disease a follow-up lasting more than five years would also reveal a survival benefit 
even when patients with unsuccessful HIPEC are included in the analysis. 
The present study noted, that more patients presented with no evidence of disease in the 
HIPEC-era group than for the debulking-era group. This might suggest that the number 
of patients who had undergone a curative treatment is also higher. The natural 
progression of the disease is slow, therefore some of the patients currently presenting 
with no evidence of disease may still suffer a relapse in the future. Consequently, the 
final evaluation of the curative potential of CRS with HIPEC combined modality would 
only be apparent after long follow-up times. 
The number of re-operations was lower among patients who underwent CRS and 
HIPEC in comparison with those who underwent serial debulking only. This finding is 
plausible. The intention of serial debulking is more palliative in intent than radical 
therefore the need for a succeeding operation is more urgent than when a radical end-
result had been achieved. On the other hand, the complication rate for HIPEC is usually 
higher than the complication rate for debulking surgery and complications often 
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necessitate re-operations over and above those required for disease progression. 
Regardless of this, the number of re-operations in our study was actually lower in the 
HIPEC-era group. 
 
These findings demonstrate that HIPEC can be considered the treatment of choice for 
selected patients with PMP. 
 
????????????????????????????????????????????????????
Classification of PMP is known to be challenging.  A pathologist’s re-assessment was 
not performed in studies I and II, thus we cannot exclude the possibility of diagnostic 
bias in those studies. If the pathological samples in studies I and II had been screened, 
some of the cases would probably have been deemed PMP of non-appendiceal origin.  
 
Our unit was the only facility that provided HIPEC in Finland during the 2008 to 2013 
period (studies III and IV). The treatment of PMP in Finland prior to that period was not 
centralized (studies I and II). Even after the commencement of HIPEC treatments in 
Finland, the numbers of patients treated in primary and secondary care units remains 
unknown. It is still possible, that patients in poor condition, or with disseminated 
disease at the time of diagnosis, were not referred to a tertiary care unit. Consequently, 
it is nearly impossible to conduct a study that involves every patient with PMP in our 
health care system. 
 
?????? ??????????????????????? ?????????
The combination of CRS and HIPEC is expensive, requires a high level of 
specialization, consumes hospital resources, and is challenging even in optimal 
circumstances. It is obvious, that HIPEC should be performed in specialized tertiary 
care units only. On the other hand, serial debulking surgery is less demanding on 
59 
hospital resources. Moreover, there is no evidence to suggest that the only facility that 
provides debulking surgery should be a tertiary care unit. Nevertheless, the assessment 
as to whether or not to attempt HIPEC should only be taken and carried out in 
specialized centers. The final decision about the treatment modality is often taken intra-
operatively during an attempt at HIPEC. Therefore, the concept of the strict 
centralization of treatment of patients with PMP is the most plausible approach for 
successfully treating this challenging disease. 
?????????????????????
The present study did not reveal survival differences in OS rates between the debulking-
era group and the HIPEC-era group after 5 years of follow-up (IV). However, the rate of 
patients who presented with no evidence of disease was higher for the HIPEC-era 
group. Thus, it is probable that those patients with no demonstrable PMP will survive 
longer than those with the disease. The natural progression of PMP is slow, thus the true 
survival benefit of the combined CRS with HIPEC treatment will become apparent only 
after follow-up lasting more than 5 years. After a prolonged follow up, the updated 
survival figures of both debulking-era and HIPEC-era groups should be compared. 
Since the adoption of HIPEC in Finland, the number of referrals has shown a huge 
increase when compared with the number of referrals during the debulking era (IV). 
According to our unpublished data, the number of new cases of verified PMP of 
appendiceal origin exceeds the excepted incidence in Finland. This effect is not 
explained by the PMP cases being diagnosed earlier and then only recently referred to 
our unit. The incidence of newly-diagnosed cases, in particular, is greater than the 
observed incidence of 1-2 / 1 000 000 annually [14]. This finding should be further 
analyzed and the age-adjusted incidence should be determined. 
Apart from patients with PMP, patients with other peritoneal malignancies have 
received CRS and HIPEC combined treatment in our unit. Selected patients with 
peritoneal mesothelioma, MANEC, carcinosis of colorectal and ovarian aetiology are 
also treated using the combined modality treatment. The outcome of those surgeries 
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should be analyzed and compared with each other and with the results of the other 
centers providing the same treatments. 
Our unit has collected a comprehensive database of patients with PMP. In addition to 
surgical data pathological samples were also collected during the present investigation. 
The present investigation noted that patients with low-grade histology managed better 
than those with high-grade histology (III, IV). It would be of interest, to find whether 
there were other factors than histological grade that affect survival. The wide 
pathological database implemented during the present investigation will enhance further 
immunohistochemical studies of the samples collected. For example, protein expression 
patterns of the samples would be interesting to study. Those patterns would include 
protein expression of V600E mutated BRAF, MLH1, MSH2, MSH6, SMAD4, and p53. 
It is possible that some of those proteins that show high frequencies of abnormal 
immunostaining are associated with survival as an independent factor. 
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????????????????
1. The 5-year OS of patients treated by serial debulking is comparable with those of
patients treated by cytoreductive surgery and HIPEC combined modality, when the 
whole patient populations were included in the analysis (I, IV). 
2. The diagnosis of PMP in the subclinical early phase is difficult and rarely achieved.
Careful patient examination including CT is highly recommended prior to the initial 
operation if there is any suspicion of intra-abdominal tumour (II). 
3. Only two thirds of patients were eligible for complete cytoreduction and HIPEC
combined treatment. The other one third of patients required treatment by other methods 
(III). 
4. Although the 5-year survival rates of serial debulking and HIPEC are comparable,
there are advantages to using HIPEC. Patients successfully treated by CRS and HIPEC 
manage well. The proportion of patients who presented with no evidence of disease was 
higher in patients treated by CRS and HIPEC combined than in patients who received 
serial debulking only at short follow-up time. This might indicate that there will be a 
survival benefit in favour of HIPEC in longer follow-up (IV). 
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This corrigendum is in reference to the manuscript Survival of patients with 
pseudomyxoma Peritonei treated by serial debulking Colorectal Dis 2010; 868-873, 
DOI: 10.1111/j.1463-1318.2009.01947.x, by P.Järvinen et al. In the published version 
of abstract (results) the number of operations should be “3.4” instead of “3.2”. A 
corrected version of the table is displayed below: 
The patients underwent an average of 3.4 ± 0.4 operations (range 1–10). 
  
? ?
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This corrigendum is in reference to the manuscript Feasibility of Radical 
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy For 
Pseudomyxoma Peritonei of Appendiceal Origin Scand J Surg 2013;102:145-151, 
DOI: 10.1177/1457496913490463,  by P. Järvinen et al. In the published version of 
Table 3 the headings “Mean age” and ‘Mean PCI’ were interchanged. A corrected 
version of the table is displayed below: 
 
TABLE 3. Comparison of means in patients undergoing successful HIPEC  
and other treatment modalities. 
  Mean age ± S.E. Median (Range) 
Student's   
t-value P N 
HIPEC 54.3 ± 1.27 54 (30-73)   56 
No 
HIPEC 61.6 ± 2.18 61 (36-87) 3.09 0.003 34 
Total           90 
  Mean PCI ± S.E. Median (Range) 
Student's   
t-value P N 
HIPEC 18.9 ± 0.83 20 (5-29)   56 
No 
HIPEC 32.6 ± 1.64 34 (16-39) 7.24 <0.001 13 
Total           69* 
  
Mean delay† ± 
S.E. Median (Range) 
Mann-
Whitney 
U P N 
HIPEC 18.3 ± 3.86 7 (0-149)   56 
No 
HIPEC 24.1 ± 7.82 3.5 (0-191) 1136.5 0.124 34 
Total           90 
HIPEC = hyperthermic intraperitoneal chemotherapy. S.E. = Standard error.  
PCI = peritoneal cancer index.  *PCI was determined only in 69 patients 
who underwent an attempt at combined modality treatment. †Delay between 
diagnosis and assessment for feasibility of HIPEC is presented in months. 
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This corrigendum is in reference to the manuscript Comparison of serial debulking 
and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in 
pseudomyxoma peritonei of appendiceal origin Int J Colorectal Dis 2014;29:999-
1007, DOI: 10.1007/s00384-014-1933-8 by P. Järvinen et al. The unit in the legend 
should be “months” instead of “years” in the published version of Figure 4. 
 
 
 
 
  
